[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 3189 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 3189

  To amend the Controlled Substances Act to place synthetic drugs in 
                              Schedule I.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                              May 16, 2012

  Mr. Portman introduced the following bill; which was read twice and 
               referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL


 
  To amend the Controlled Substances Act to place synthetic drugs in 
                              Schedule I.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Synthetic Drug Control Act of 
2012''.

SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I OF THE CONTROLLED 
              SUBSTANCES ACT.

    (a) Cannabimimetic Agents.--Schedule I, as set forth in section 
202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended 
by adding at the end the following:
    ``(d)(1) Unless specifically exempted or unless listed in another 
schedule, any material, compound, mixture, or preparation which 
contains any quantity of cannabimimetic agents, or which contains their 
salts, isomers, and salts of isomers whenever the existence of such 
salts, isomers, and salts of isomers is possible within the specific 
chemical designation.
    ``(2) In paragraph (1):
            ``(A) The term `cannabimimetic agents' means any substance 
        that is a cannabinoid receptor type 1 (CB1 receptor) agonist as 
        demonstrated by binding studies and functional assays within 
        any of the following structural classes:
                    ``(i) 2-(3-hydroxycyclohexyl)phenol with 
                substitution at the 5-position of the phenolic ring by 
                alkyl or alkenyl, whether or not substituted on the 
                cyclohexyl ring to any extent.
                    ``(ii) 3-(1-naphthoyl)indole or 3-(1-
                naphthylmethane)indole by substitution at the nitrogen 
                atom of the indole ring, whether or not further 
                substituted on the indole ring to any extent, whether 
                or not substituted on the naphthoyl or naphthyl ring to 
                any extent.
                    ``(iii) 3-(1-naphthoyl)pyrrole by substitution at 
                the nitrogen atom of the pyrrole ring, whether or not 
                further substituted in the pyrrole ring to any extent, 
                whether or not substituted on the naphthoyl ring to any 
                extent.
                    ``(iv) 1-(1-naphthylmethylene)indene by 
                substitution of the 3-position of the indene ring, 
                whether or not further substituted in the indene ring 
                to any extent, whether or not substituted on the 
                naphthyl ring to any extent.
                    ``(v) 3-phenylacetylindole or 3-benzoylindole by 
                substitution at the nitrogen atom of the indole ring, 
                whether or not further substituted in the indole ring 
                to any extent, whether or not substituted on the phenyl 
                ring to any extent.
            ``(B) Such term includes--
                    ``(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
                hydroxycyclohexyl]-phenol (CP-47,497);
                    ``(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-
                hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-
                47,497 C8-homolog);
                    ``(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and 
                AM678);
                    ``(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-073);
                    ``(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);
                    ``(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-
                naphthoyl)indole (JWH-200);
                    ``(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole 
                (JWH-250);
                    ``(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole 
                (JWH-081);
                    ``(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole 
                (JWH-122);
                    ``(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-
                398);
                    ``(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole 
                (AM2201);
                    ``(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole 
                (AM694);
                    ``(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole 
                (SR-19 and RCS-4);
                    ``(xiv) 1-cyclohexylethyl-3-(2-
                methoxyphenylacetyl)indole (SR-18 and RCS-8); and
                    ``(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole 
                (JWH-203).''.
    (b) Other Drugs.--Schedule I of section 202(c) of the Controlled 
Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by 
adding at the end the following:
            ``(18) 4-methylmethcathinone (Mephedrone).
            ``(19) 3,4-methylenedioxypyrovalerone (MDPV).
            ``(20) 3,4-methylenedioxymethcathinone (methylone).
            ``(21) Naphthylpyrovalerone (naphyrone).
            ``(22) 4-fluoromethcathinone (flephedrone).
            ``(23) 4-methoxymethcathinone (methedrone; Bk-PMMA).
            ``(24) Ethcathinone (N-Ethylcathinone).
            ``(25) 3,4-methylenedioxyethcathinone (ethylone).
            ``(26) Beta-keto-N-methyl-3,4-benzodioxyolybutanamine 
        (butylone).
            ``(27) N,N-dimethylcathinone (metamfepramone).
            ``(28) Alpha-pyrrolidinopropiophenone (alpha-PPP).
            ``(29) 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).
            ``(30) 3,4-methylenedioxy-alphapyrrolidinopropiophenone 
        (MDPPP).
            ``(31) Alpha-pyrrolidinovalerophenone (alpha-PVP).
            ``(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) 
        (MDAI).
            ``(33) 3-fluoromethcathinone.
            ``(34) 4'-Methyl-a-pyrrolidinobutiophenone (MPBP).
            ``(35) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).
            ``(36) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).
            ``(37) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).
            ``(38) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).
            ``(39) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-
        T-2).
            ``(40) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 
        (2C-T-4).
            ``(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).
            ``(42) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).
            ``(43) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-
        P).''.

SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT HAZARDS TO PUBLIC SAFETY 
              EXPANSION.

    Section 201(h)(2) of the Controlled Substances Act (21 U.S.C. 
811(h)(2)) is amended--
            (1) by striking ``one year'' and inserting ``2 years''; and
            (2) by striking ``six months'' and inserting ``1 year''.
                                 <all>